ANNOUNCEMENTS

ASN CONFERENCE

The American Society of Nephrology is sponsoring an ASN conference on “Moving Things Around: The Structural Basis of Trafficking” to be held November 17–20, 1993 at the Chatham Bars Inn, Chatham, MA. Conference organizers are Dennis Brown and Jenifer Stow. For general information or information regarding trainee and young investigator travel awards, contact Martha Wagner, ASN Headquarters, 1101 Connecticut Ave NW, Washington, DC 20036.

SEVENTH INTERNATIONAL CONGRESS ON NUTRITION AND NUTRITION IN RENAL DISEASE

The Seventh International Congress on Nutrition and Metabolism in Renal Disease will be held May 29–June 1, 1994, in Stockholm, Sweden. The Scientific Programme for Nephrologists, Dietitians, and Allied Professionals will include: State-of-the-Art Lectures, Symposia, Free Communications, and Poster Sessions. For more information, please contact: Anders Alvestrand, M.D., The Secretariat, 7th I.C.N.M.R.D., Department of Renal Medicine, Karolinska Institute, Huddinge University Hospital K56, S-141 86 Huddinge, Sweden. Tel. +46 8 7462609; FAX +46 8 7114742.

AMERICAN BOARD OF INTERNAL MEDICINE

1994 Certification and Recertification Examinations in Internal Medicine

<table>
<thead>
<tr>
<th>Registration Period:</th>
<th>September 1, 1993–December 1, 1993</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examination Dates:</td>
<td></td>
</tr>
<tr>
<td>Certification Exam.</td>
<td>August 23, 24, 1994</td>
</tr>
<tr>
<td>Recertification Exam.</td>
<td>August 23, 1994</td>
</tr>
</tbody>
</table>

1994 Certification and Recertification Examinations in Clinical Cardiac Electrophysiology, Hematology, Infectious Disease, Nephrology, Pulmonary Disease, and Rheumatology

<table>
<thead>
<tr>
<th>Registration Period:</th>
<th>January 1, 1994–April 1, 1994</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examination Date:</td>
<td>November 10, 1994</td>
</tr>
</tbody>
</table>

For more information and application forms, please contact: Registration Section, American Board of Internal Medicine, 3624 Market Street, Philadelphia, PA 19104; Telephone: 1-(800)-441-2246; 1-(215)243-1500.

STUDENT SCHOLARSHIPS IN KIDNEY DISEASE

The Council on The Kidney in Cardiovascular Disease of the American Heart Association is offering student scholarships to study kidney disease. The objective of these scholarships is to stimulate medical students to study the kidney and its diseases in an investigational setting. The scholarships can support special clinical training or clinical or laboratory research in kidney diseases. It is intended that students devote at least 2 months to the project. Selection will be based on the proposal and the supervision provided by a responsible preceptor. The amount of the stipend is $1,500. Applications must be postmarked no later than April 1, 1994. For further information contact: Verna Craven, American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231. Phone (214) 706-1261.
ACKNOWLEDGMENT OF MANUSCRIPT CONSULTANTS
JASN VOLUME 3

Peer review of another's work is a responsibility of those who wish to publish material of their own. It is with pleasure and deep gratitude that I publicly acknowledge those who have advised the editorial staff during the past year.

Jared J. Grantham, M.D.
Editor, JASN

Hanna Aboub
Ruth Abramson
Sharon Adler
Stephen Adler
Robert Alpern
Nathaniel Alpers
William Amend
Sharon Anderson
Sharon Andreoli
Dennis Andrews
Anita Aperia
William Arendshorst
Jeffrey Askanazi
George Bakris
Barbara Ballermann
James Balow
Steven Bander
William Baricos
Daniel Battle
Christine Baylis
F. Darwin Bell
William Bennett
Dale Benos
Jay Bernstein
Kenneth E. Bernstein
John Bertolatus
Alejandro Bertorello
Peter C. Blake
Roland Blantz
Kline Bolton
Wayne Border
Juan Bosch
Jacque Bourgoigne
James C. Brandes
Dennis Brown
Vardaman Buckalew
Maurice Burg
John C. Burnett
David Bushinsky
James P. Calvet
Vito Campese
Pamela Carmines
John J. Castellot
Alfred Cheung
Michael Chobanian
Thomas Coffman
R. Edward Coleman
Robert Colvin
John Conger
Fernando Coslo
Ramzi Cotran
William G. Couser
Catherine C. Cowie
Benjamin Cowley
Gabriel Danovitch
John T. Daugirdas
Ingeca Davidson
James Delmez
Thomas A. Depner
Jose Diaz-Buxo
Dennis Diederich
Jesus Dominguez

Thomas Dousa
Thomas DuBose, Jr.
Alan Dubrow
Carlos DuBovne
Francis Dumler
Michael J. Dunn
Lance Dwarkin
Richard Edwards
Susan Fellner
Arnold Felsenfeld
M. Roy First
Annette Fitz
Michael Flesner
Agnes Fogo
Linda Francisco
Ell Friedman
Peter Friedman
Gustavo Frindt
Patricia Gabow
Raymone Gagnon
Kenneth Gardner
Lal Garg
V. Joyce Gauthier
Frank Gesek
Stephen Gluck
Michael Goligorsky
Thomas Golper
David Good
Gordon R. Grahame
J. P. Granger
M. C. Gregory
Steven Gullans
Raymond Hakim
Joseph S. Handler
Avidan Haramati
Ray Harris
William S. Harris
John J. Hassell
Lee Henderson
William Henrich
Daniel R. Hinthorn
Raimond Hirschberg
Michael K. Hise
Jean Holley
Suk K. Hong
Thomas Hostetter
Donald Hricik
Keith Hruska
Michael Humphreys
Lawrence Hunsicker
Todd Ing
Kathy Jabs
Charles Jennette
Anthony Jevnikar
Richard Johnson
Stanley C. Jordan
Pedro A. Jose
Bruce Julian
Louis Justement
Yashpal Kanwar
Andre Kaplan
Balakuntalam Kasinath

George Kaysen
William Keane
Carl Kjellstrand
Jon B. Klein
Paul Klotman
Mark Knepper
Franklyn Knox
Sydney Kobrin
Donald Kohan
Valentina Kon
Stephen Korbet
Theodore Kotchen
Zoltan Laszik
Harold Layton
Michael Lazarus
James Lefkowith
Jacob Lemann
Mortimer Levy
Wilfred Lieberthal
Yeong Hau Lien
Meyer Lifschitz
Stuart Linas
James Lohr
Christopher Lu
Margaret MacDougall
Ronal MacGregor
Michael Madalo
Kirsten Madsen
Deepak Malhotra
Hartmut Malluche
Lazero Mandel
Philip A. Marsden
Kevin Martin
Manuel Martinez-Maldonado
Robert May
T. Dwight McKinney
Ravinda Mehta
Paolo Mene
Timothy Meyer
Richard Millman
William Mitch
Leon Moore
Bryan Myers
Tibor Nadasdy
Glenn Nagami
Karl A. Nath
Eric G. Neison
John Neylan, III
Allen Nissenson
Karl Nolphi
Edward P. Nord
Douglas J. Norman
Dimitrios Oreopoulos
Emil Paganini
Mark S. Paller
Patrick Parfrey
Ronald D. Perrone
Diana Philbrick
Beth Piraino
Friedrich K. Port
John B. Pritchard
Lawrence Rabinowitz

Leopoldo Raji
Rasib Raja
T. K. S. Rao
Garry Reams
Giuseppe Remuzzi
Richard Rettig
Robert Richardson
Robert Riggio
Eberhard Ritz
Richard Roman
J. Carlos Romero
David Rothstein
Brad Rodriguez
John Sadler
David Salant
Virginia Savin
Paul Schloerb
Jorgen Schernmann
Martin Schreiber
Gerald Schulman
Pamela Schultz
Victor Schuster
Steve Schwab
John Sedor
Joseph I. Shapiro
Donald Sherrard
Normal Siegel
Fred Silva
Melvin Silverman
Peter Singer
Kim Slezek
Darro Sorrentino
Michael Steffes
John Stivelman
John Stokes
Liliane Striker
Manikkan Suthanthiran
Richard Tannen
Amir Tejani
George Tempel
Lillian Thompson
F. Gary Toback
Jonathan Tolins
Vicente Torres
Howard Trachtman
Carlos Vaamonde
John C. Van Stone
James Vogt
Mackenzie Walser
Karl T. Weber
Joel Weinberg
Matthew R. Weir
Thomas Wiegmann
Christopher Wilcox
Barry Wilkes
Curtis Wilson
James Winchester
Jay Wish
Pancras Wong
Richard Zager
Mark Zeitel
Randall Zusman
VOLUME 3
AUTHOR INDEX

Abrams, J., 1608
Adica, C., 1342
Agodoa, L., 1961
Ahststrom, N. G., 1878
Alay, N., 1643
Albrighton, C. R., 1680
Alcazar, J. M., 1307
Aldebrete, G., Jr., 1156
Al-Ghraoul, F., 1351
Allon, M., 1555
Almashari, K., 1878
Ammer, U., 1474
Amuchastegui, S., 1710
Anderson, J., 103
Anderson, S., 214, 1333, 1775, 586
Antignani, A., 1613
Araki, S.-I., 5120
Arbeit, L., 1563
Ardallou, R., 1873
Arias, R., 1563
Arkonoff, G. R., 1583
Atkins, R. C., 1765
Aultzky, W. K., 1163
Austin, S. M., 1358
Aviv, A., 1049
Avram, M. M., 1613

Baba, T., 564
Badger, A. M., 1680
Badr, K. F., 1496
Bain, R., 979
Balakrishnan, K., 1220
Barakat, M. M., 1813
Bardin, C. W., 1163
Barr, M., Jr., 1574
Bass, E. B., 1660
Bastani, B., 264
Baud, L., 1783
Bay, W. H., 103
Baylis, C., 1835
Beavis, J., 1954
Beierwaltes, W. H., 1288
Bellucci, A. G., 1631
Benatti, L., 1710
Bennett, P. H., 229
Berger, M., 554
Berson, L., 1607
Bertani, T., 1458
Best, C., 1680
Bia, M. J., 1653
Blake, J. W., 236
Blake, P. G., 1501
Blake, R. M., 1501
Blanton, M., 1220
Blantz, R. C., 1686
Bluestone, P. A., 1631
Bolino, F. G., 1522
Boitard, C., 534

Bonventre, J. V., 128
Bosch, J. P., 1244
Bosworth, C., 1516
Bourgoignie, J. J., 1819
Brands, M. W., 1064
Bredl, C. R., 116
Brennan, D. C., 35
Brenner, B. M., 162, 214, 1775
Brezis, M., 58
Brier, M. E., 1583
Briscoe, D. M., 1180
Brocco, E., 556
Buddemeyer, E. U., 108
Bunke, C. M., 1583
Burg, M. B., 121
Burrett, J. C., Jr., 196
Burrell, D., 1613
Butler, G. C., 1672
Buxton, D. B., 1295

Cameron, R., 1279
Canaan-Kuhl, S., 236
Canessa, M., 541
Canzanello, V. J., 1457
Capdevila, J. H., 1496
Capraro, F. E., 1878
Carone, F. A., 244
Carretero, O. A., 1288
Casal, M. C., 1307
Casella, F. J., 1555
Cattano, C., 1416
Chan, J. C. M., 1428
Chapman, A., 1858
Chauveau, D., 1119
Cheema-Dhadi, S., 1212
Chen, B. C., 1295
Chen, C.-L. C., 1163
Chen, X.-W., 1105
Chen, Y., 1488
Cheng, C. Y., 1163
Chemew, M., 1227
Cheung, A. K., 1884
Chima, C. S., 1516
Christlieb, A. R., 104
Cichon, Z., 1163
Cipollina, M. R., 556
Clark, B. A., 58
Clark, W. F., 1321
Coffman, T., 1972
Coffman, T. M., 1680
Cohen, E. P., 264
Cohen, M. R., 264
Cohen, R. A., 162
Cohen, R. J., 1354
Coles, G. A., 1508, 1954
Collier, J., 1613
Conger, J. D., 1792
Correa-Rotter, R., 1172
Costello, J. R., 1098

Cotran, R. S., 1180
Cox, D., 1947
Cragoe, E. J., Jr., 1124
Culpepper, R. M., 151
Curtis, J. C., 1570
Cybulsky, A. V., 1398
Cybulsky, M. I., 1398

Dalmasso, A. P., 1189
Daniels, F. X., 1694
Daugirdas, J. T., 1813
Davies, J. E., 550
Decap, G., 1307
Deen, W. M., 214
de Jong, P. E., 1333
Delmez, J. A., 96
Devault, G. A., Jr., 1884
de Zeeuw, D., 1333
Diaz-Buxo, J. A., 1039
Dibona, G. F., 188
Dimitrakoudis, D., 1078
Doria, A., 59, 556
Dousa, T. P., 1253
Dréke, T., 182
Dudley, C. R. K., 52
Duley, I. T., 1863

Earle, K., 527
Ebihara, I., 1378, 1387
Edwards, R. M., 1643
Emans, J., 1938
Epstein, F. H., 58
Epstein, M., 42
Espeland, M. A., 1467
Evans, J., 1467

Fadda, G. Z., 1139
Falk, S. A., 1792
Fan, P.-Y., 1, 1680
Feld, L., 51
Feng, L., 1753
Fenoy, F. J., 66
Femandes, M. H., 1591
Rick, G. M., 1863
Fine, A., 1947
Fine, L. G., 1124
Fiorotto, P., 1694, 556
First, M. R., 1220
Fisler, D., 1371
Flowerdew, G., 1501
Foerder, C. A., 116
Fontaine, B., 1947
Fouqueray, B., 1783
Frankl, N., 80
Freedman, B. I., 1467
Frigo, F., 556
Fukui, M., 1387
Futterweit, S., 1913

Gabow, P. A., 1863

Gahl, G. M., 1508
Gainza, F. J., 1638
Gambara, V., 1458
Ganda, O. P., 5104
Garber, A. M., 1227
Garcia-Perez, A., 121
Garg, L. C., 170
Gaston, R. S., 1570
Geberth, S., 1119, 1451
Geiler, R. L., 1119
Germano, G., 1295
Gibbons, N., 80
Giles, K. S., 96
Gillespie, K. N., 1113
Gluffra, L. A., S2
Gilimcher, L. H., 1972
Gloviczki, P., 196
Gluck, S. L., 264
Goldberg, I. J., 1409
Goldstein, M., 1163
Goldwasser, P., 1613
Gong, R., 1808
Gonzalo, A., 1119
Goodman, W., 1386
Gopinath, R., 1212
Gordon, J. A., 35
Gough, S., 1808
Grantham, J. J., 1843
Greene, T., 1819
Gregory, M. C., 1884
Griffiths, R. I., 1660
Grinfeld, J. P., 1119
Gruber, K. K., 1156
Gründfeld, P., 534
Guichney, P., 534
Guirre, K. E., 1147
Gullans, S. R., 1913

Habwe, V., 1819
Haffner, S. M., 1156
Hakim, R., 1563
Hall, A. V., 1321
Hall, J. E., 1064
Haller, H., 1312
Halperin, M., 1212
Hanedo, M., 5120
Hanna, J. D., 1428
Hannedouche, T., 182
Hannedouche, T. P., 534
Hansen, H. W., 1295
Harman, W., 1938
Harmon, W. E., 260, 1180
Harris, R. C., 1496
Hanwood, J. L., 1954
Hashim, S. A., 1409
Hashimoto, Y., 42
Hawkins, R. A., 1295
Haynie, J. D., 1978
Hays, R. M., 80

1984 Volume 3 • Number 12 • 1993
thromboxane receptor antagonism, rats with congenital
hydronephrosis, 1522
vasoactive substances, induction of cytoskeletal changes,
rat glomerular epithelial cells, 1131
Anions, palmitate transport, rat renal basolateral membrane
vesicles, presence of albumin, 1920
Antibodies, natural, natural immune barrier, xenotransplant-
tion, 1189
Antihypertensive therapy
cost-effectiveness of screening and early treatment, neph-
ropathy, insulin-dependent diabetes mellitus, S111
experimental diabetes, S86
mild to moderate hypertension, generalizability to dia-
betics, S135
prevention of progression of microalbuminuria, proteinuria,
insulin-dependent diabetes, S91
Antinatriuresis, erythropoietin-induced, mediation by angio-
tensin II, perfused kidneys, 1583
Anuria, angiotensin-converting enzyme inhibitor fetopathy,
1575
Apoptosis, clusterin production, loss of renal function, ob-
structed rabbit kidney, 1163
Arachidonate, cytochrome P450 epoxygenase induction,
uninephrectomy, counterregulation of hyperfiltration,
1496
Arachidonic acid, phospholipase A2 and signal transduction,
128
Arecoline, characterization of cholinergic receptors, Madin-
Darby canine kidney cells, 170
L-Arginine, erythropoietin effect, hematocrit and blood pres-
sure, normotensive and hypertensive rats, 182
Arginine vasopressin, angiotensin II and, effects on F-actin
content, mesangial cells, 80
Arteriolar
acetylcholine-induced vasodilation, renal microvessels, cy-
clonixoxide-treated rats, 42
rat renal, smooth muscle calcium, angiotensin II-induced
changes, 1792
Arteriosclerosis, heterogeneous nature of renal lesions, type
II diabetes, 1458
Aspartate, acid-base regulation, hepatic glutamine metab-
olism, ureagenesis, 1416
Atherosclerosis
idiopathic retroperitoneal fibrosis, 1748
improvement of plasma lipoprotein profiles, high-flux di-
alysis, 1409
Atrial natriuretic factor, modulating action, endothelin,
model of acute ischemic renal dysfunction, 196
Atrial natriuretic peptide
cGMP accumulation in the kidney, effect of urodilatin, 1705
cyclophilin-like gene expression, sodium excretion
changes, nephrosis, 1710
induction of endothelin release, radiocontrast agents, 58
inhibitory role, angiotensin II-induced proliferation, cultured
murine mesangial cells, 1270
peptides from N-terminal region, procoptidemelanocortin,
acute unilateral nephrectomy, 1105
regulation of platelet clearance receptors, diabetic neph-
ropathy, 236
vasoactive substances, induction of cytoskeletal changes,
rat glomerular epithelial cells, 1131
Atropine, characterization of cholinergic receptors, Madin-
Darby canine kidney cells, 170
Autoimmunity, initiation of immune renal injury, transgenic
tubular cell expression, class II, 1972
Autoregulation, biochemical and tissue aspects, interleu-
kine-1-induced alterations, glomerular proteoglycans, 203
Azaspirane, SKF 105685, amelioration, renal allograft rejec-
tion in rats, 1680
AZT, AIDS and mitochondrial myopathy, chronic lactic aci-
dosis, 1212
Basement membrane, tubular cells and, sequential changes,
polycystic kidney disease, 244
Basolateral membrane, renal vesicles, palmitate transport,
presence of albumin, 1920
Behavior, chronic in-center hemodialysis patients’ attitudes,
knowledge of, advance directives, 1405
Betaine, how tonicity regulates gene expression, 121
Bicarbonate, dialysate, normalization of uremic acidosis, he-
modialysis patients, 1804
Blood
flow, see Blood flow
gases, normalization of uremic acidosis, hemodialysis pa-
tients, 1804
pressure, see Blood pressure
recirculation, intravenous catheters, hemodialysis, 1978
volume, endothelial albumin leakage, cyclosporine, 51
Blood flow
cyclosporine-treated hypertensive patients, captopril-in-
duced fall, glomerular filtration rate, 1570
induction of renal arachidonate cytochrome P450 epoxy-
genase, uninephrectomy, counterregulation of hyperfil-
tration, 1496
renal, N-13 ammonia PET, two-compartment model, 1295
vascular access, concepts for the 1990s, 1
Blood pressure
effects of fructose feeding, glomerular structure, rats, 1330
experimental hypertension, gene mapping, 28
hematocrit and, effect of erythropoietin, normotensive and
hypertensive rats, 182
hemodynamic effects, intradialytic food ingestion, effects
of caffeine, 1813
human essential hypertension, identification, genetic de-
terminants, S2
hypertension, obesity, insulin resistance, 1064
hypertension and insulin resistance, obesity and diabetes,
cellular ions, S78
modification of diet, baseline characteristics, renal disease,
1819
normal, insulinoma despite hyperinsulinemia and insulin re-
stance, S64
reduction, cyclosporine nephrotoxicity, rat, 1892
Blood-brain barrier, regulation of solute and water balance,
cell volume, central nervous system, 12
Bone
extrarenal clearance of oxalate, progression of renal fail-
ure, rat, 1098
renal disease, hemodialysis, pediatric and young adult pa-
tients, 1938
Bradykinin, generation by dialysis membranes, possible role,
anaphylactic reaction, 1563
Brain
cerebral cell volume, role of organic osmolytes, acute and
chronic renal failure, 1913
induction of hyponatremia, vasopressin or desmopressin,
1600
regulation of solute and water balance, cell volume, 12
Brush border membrane
phosphate transport, response to phosphonoformic acid,
uremic rats, 1253
renal and intestinal P, transport adaptation, low phosphorus
diet, uremic rats, 1930
Caffeine, hemodynamic effects, intradialytic food ingestion,
Calcitriol
calcium acetate as a phosphorus binder, hemodialysis patients, 96
kidney in sarcoidosis, 1555
Calcium
antagonism, prevention of microalbuminuria progression to overt proteinuria, IDDM, S94
chronology of cellular events, derangements in pancreatic islet function, chronic renal failure, 1139
elevation of serum phosphate, parathyroid hormone levels, hemodialysis, 1947
hypertension and insulin resistance, obesity and diabetes, S78
phospholipase A2 and signal transduction, 128
protein kinase C and N+-H+ antiport, development of hypertension, insulin resistance, 1049
smooth muscle, angiotensin II-induced changes, rat kidney, 1792
Calcium acetate, phosphorus binder in hemodialysis patients, 96
Capillary
glomerular
glomerulosclerosis, in fawn-hooded rat, 1775
measurement of albumin reflection coefficient, 1260
Captopril
angiotensin-converting enzyme inhibitor fetopathy, 1575
controlled clinical trial, type I diabetic nephropathy, S97
ethyropoetin-induced antinatriuresis, mediation by angiotensin II, perfused kidneys, 1583
- induced fall in glomerular filtration rate, cyclosporine-treated hypertensive patients, 1570
tubuloglomerular feedback and, remnant kidneys, prehypertensive rats, 73
Carbachol, characterization of cholinergic receptors, Madin-Darby canine kidney cells, 170
Catheter
intravenous, blood recirculation, hemodialysis, 1978
peritoneal dialysis, placement under peritoneoscopic visualization, modification of approach, 103
Cell volume, solute and water balance, regulation, central nervous system, 12
Central nervous system, regulation, solute, water balance and cell volume, 12
Chloride, pathogenesis of renal epithelial cysts, fluid secretion, cellular proliferation, 1843
Cholesterol
coronary artery disease and excess mortality, persistent proteinuria, IDDM, S104
serum, predictors of mortality, hemodialysis patients, 1613
Choroid plexus, solute and water balance, cell volume regulation, central nervous system, 12
Circulation
predisposition to essential hypertension, recent-onset insulin-dependent diabetes, S34
vascular access, concepts for the 1990s, 1
Clusterin
complement interaction, renal injury, 1172
production in obstructed rabbit kidney, correlations, loss of renal function, 1163
Coagulopathy, omega-3 fatty acid supplementation, primary nphartotic syndrome, 1321
Collagen, extracellular matrix component mRNA expression, glomeruli, experimental focal glomerulosclerosis, 1387
Collecting ducts
inner medullary cGMP accumulation, effect of urodilatin, 1705
diabetes induced production, 1719
Collecting tubes, cortical, regulation of renal Na:K pump, role of progesterone, 1488
Complement
clusterin interaction, renal injury, 1172
production of endothelin-1, glomerular epithelial cells, 1398
Converting enzyme inhibitor, captopril-induced fall, glomerular filtration rate, cyclosporine-treated hypertensive patients, 1570
Coronary artery disease
hypertension and, non-insulin dependent diabetes, cause and effect, S126
major determinant of excess mortality, insulin-dependent diabetes mellitus, persistent proteinuria, S104
Coronary heart disease, increased lipoprotein(a) concentrations, chronic renal failure, 1156
Creatine
clearance
dietary protein, renal function, 1723
dietary protein intake, 1638
extrarenal clearance of oxalate, progression of renal failure, rat, 1098
Cuprammonium, eosinophilia and cytokine responsiveness, hemodialysis, 1244
Cyclic AMP
angiotensin II-induced proliferation, inhibitory role of atrial natriuretic peptide, cultured murine mesangial cells, 1270
characterization of cholinergic receptors, Madin-Darby canine kidney cells, 170
vasoactive substances, induction of cytoskeletal changes, rat glomerular epithelial cells, 1131
Cyclic GMP
accumulation in the kidney, effect of urodilatin, 1705
regulation of platelet clearance receptors, atrial natriuretic peptide, diabetic nephropathy, 236
vasoactive substances, induction of cytoskeletal changes, rat glomerular epithelial cells, 1131
Cyclophilin-like protein gene expression, sodium excretion changes, nephrosis, 1710
Cyclosporin A, inhibition of efficacy in children, severe hypercholesterolemia, nephrotic syndrome, 254
Cyclosporine
endothelial albumin leakage in rats, 51
nephrotoxicity, effects of blood pressure reduction, rat, 1892
renal transplant patients, treatment of hypercholesterolemia, Lovastatin, 1884
-treated hypertensive patients, captopril-induced fall, glomerular filtration rate, 1570
-treated rats, acetylcholine-induced vasodilatation, renal microvessels, 42
Cyst, autosomal dominant polycystic kidney disease, 1442
Cytochrome P450, phospholipase A2 and signal transduction, 128
Cytochrome P450 epoxygenase, arachidonate, induction after nephrectomy, counterregulation of hyperfiltration, 1496
Cytokines
angiotensin II as a renal growth factor, 1531
formation within rat glomeruli, experimental endotoxemia, 1783
inhibition of phagocyte function, peritoneal dialysis fluid, 1508
responsiveness, eosinophilia, hemodialysis, 1244
Cytoskeleton
changes induced by vasoactive substances, rat glomerular epithelial cells, 1131
changes in epithelial cells, 1839
Cytotoxic T lymphocytes, flow cytometry, acute renal graft rejection, 1220
Dantrolene, angiotensin II-induced changes, smooth muscle calcium, rat renal arterioles, 1792
Decision-making, advance directives, association with "good deaths," chronic dialysis patients, 1623
Deferoxamine, renal bone disease, hemodialysis, pediatric and young adult patients, 1938
Deoxyspergualin, suppression, experimental crescentic glomerulonephritis, 1765
Desmopressin, vasopressin or, induction of hyponatremia, 1600
Dextran
dermination of glomerular size-selectivity, Ficoll, rats, 214
hypertonic saline solutions and, dialysis-induced hypertension, 1808
slope of serial glomerular filtration rate, progression, diabetic glomerular disease, 1358
Diabetes mellitus
associated hypertension, past and future, S1
awoke nondiabetic and diabetic rats, acute insulin infusion, renal function, 1686
death by withdrawal from dialysis, 1631
development of nephropathy, predisposition, essential hypertension, S27
experimental, antihypertensive therapy, S86
experimental non-insulin dependent, alterations, glomerular proteoglycan metabolism, 1694
hyperglycemia effects, glucose transporters of the muscle, phlorizin, 1078
hypertension and, molecular biology techniques, renin-angiotensin system, S18
increased lipoprotein(a) concentrations, chronic renal failure, 1156
insulin-dependent
cost-effectiveness of screening and early treatment, nephropathy, S111
molecular genetic approaches, development of nephropathy, S9
persistent proteinuria and coronary artery disease, excess mortality, S104
predisposition to essential hypertension, renal hemodynamics, S34
prevention of microalbuminuria progression to overt proteinuria, antihypertensive therapy, S91
insulin resistance and hypertension, roles of cell Ca²⁺, protein kinase C and Na⁺/H⁺ antiporter, 1049
nephropathy
abnormalities, Na⁺/H⁺ antiporter activity, S50
controlled clinical trial, angiotensin-converting enzyme inhibition, S97
early course of, clinical clues, 1356
large glomerular size, Pima Indians, 229
racial variation, human leukocyte antigen frequency, 1467
regulation of platelet clearance receptors, atrial natriuretic peptide, 236
non-insulin dependent
close relationship, microalbuminuria and insulin resistance, S56
hypertension and development of complications, Japan, S120
obesity and, hypertension and insulin resistance, cellular ions, S78
pharmacologic therapy, mild to moderate hypertension, S135
progression of glomerular disease, slope of serial glomerular filtration rate, 1358
sodium inactivation kinetics, red blood cell Na⁺/Li⁺ countertransport, S41
type II, heterogeneous nature of renal lesions, 1458
Dialysate, high bicarbonate, normalization of uremic acidosis, hemodialysis patients, 1804
Dialysis
chronic, advance directives, "good deaths," 1623
continuous ambulatory peritoneal compared to hemodialysis, patient survival and trends in 1980s, 1147
intraperitoneal phosphatidylcholine levels, ultrafiltration adequacy, 1954
long-term therapy, end-stage renal disease, 1039
peritoneal dialysis catheter placement, peritoneoscopic visualization, 103
serum albumin, outcomes, 1501
unusual cases of peritonitis, Listeria monocytogenes, 1092
death by withdrawal from, 1631
high-flux
improvement, plasma lipoprotein profiles, 1409
multivariate analysis, mortality and hospital admissions, 1227
-induced hypotension, hypertonic saline solutions, dextran, 1808
membranes, bradykinin generation, role in anaphylactic reaction, 1563
outcomes of cardiopulmonary resuscitation, 1238
peritoneal, end-stage renal disease, variation in outcomes, 1738
peritoneal dialysis fluid, inhibition of phagocyte function, 1508
platelet production, effect, recombinant human erythropoietin, 1672
preemptive bilateral nephrectomy and, before renal transplantation, congenital nephrotic syndrome, 260
venous pressure, vascular access, concepts for the 1990s, 1
Diet
fish oil, amelioration, ischemic acute renal failure, 1312
glomerular preload and afterload reduction, tool to lower urinary protein leakage, 1333
intradiatomic food ingestion, hemodynamic effects, caffeine, 1813
low phosphorus, renal and intestinal P, transport adaptation, uremic rats, 1930
low protein intake, converting enzyme inhibition, additive antiproteinuric effect, 1307
modification, baseline characteristics, renal disease study, 1819
potassium chloride, borderline hypertensive rats, 188
protein, renal function and, 1723
protein intake and creatinine clearance, 1638
Diethylenetriaminopentaacetic acid, radiolabeled methods, simultaneous measurements, glomerular filtration rate, 108
3,4-Dihydroxyphenylacetic acid, involvement of tubular sodium, formation of dopamine, human renal cortex, 1591
L-Dihydroxyphenylalanine, involvement of tubular sodium, formation of dopamine, human renal cortex, 1591
Diltiazem, angiotensin II-induced changes, smooth muscle calcium, rat renal arterioles, 1792
Diuresis, postdiuretic sodium retention, volume-independent component, humans, 1878
Dopamine, formation, involvement of tubular sodium, human renal cortex, 1591
DUP 753, angiotensin II-induced proliferation, inhibitory role of atrial natriuretic peptide, cultured murine mesangial cells, 1270
Economics, cost implications to Medicare, erythropoietin therapy, anemia of end-stage renal disease, 1660

Editorials
Angiotensin II as a Renal Growth Factor, 1531
Angiotensin II Receptor Subtypes in the Kidney, 1643
Clinical Clues to Understanding the Early Course of Diabetic Nephropathy, 1356
Dietary Protein and Renal Function, 1723
Endothelium-Derived Relaxing Factor, Nitric Oxide: Effects on and Production by Mesangial Cells and the Glomerulus, 1435
Gene Mapping in Experimental Hypertension, 28
Glomerular Prefeed and Afterload Reduction as a Tool to Lower Urinary Protein Leakage: Will Such Treatments Also Help to Improve Renal Function Outcome? 1333
How Tonicity Regulates Gene Expression, 121
Infectious Morbidity and Defects of Phagocytic Function in End-Stage Renal Disease: A Review, 1541
Intercellular Adhesion Molecules and Vascular Cell Adhesion Molecule-1 and the Kidney, 1201
Is Continuous Ambulatory Peritoneal Dialysis Adequate Long-Term Therapy for End-Stage Renal Disease? A Critical Assessment, 1039
Phospholipase A2 and Signal Transduction, 128
Regulation of Solute and Water Balance and Cell Volume in the Central Nervous System, 12
Remnant Kidney Oxygen Consumption: Hypermetabolism or Hyperbole?, 151
The Natural Immune Barrier to Xenotransplantation, 1189
The Roles of Cell Ca**, Protein Kinase C and the Na**H** Antiport in the Development of Hypertension and Insulin Resistance, 1049
Vascular Access: Concepts for the 1990s, 1

Eicosanoids
amelioration of ischemic acute renal failure, dietary fish oil administration, 1312
amelioration of renal allograft rejection, azaspirane SKF 105685, rats, 1680
phospholipase A2 and signal transduction, 128
Elderly, see Aging
Electrophysiology, functional integrity, proximal tubule cells, 1900

Endapril
angiotensin-converting enzyme inhibitor fetoapathy, 1575
converting enzyme inhibition, additive antiproteinuric effect, low protein intake, 1507
Endothelin
induction of release, radiocontrast agents, 58
model of acute ischemic renal dysfunction, modulating action, atrial natriuretic factor, 196
production, human inner medullary collecting duct cells, 1719
Endothelin-1, production by glomerular epithelial cells, 1398
Endothelium
acetylcholine-induced vasodilation, renal microvessels, cyclosporine-treated rats, 42
albumin leakage, effect of cyclosporine, rats, 51
VCAM-1 expression, renal allografts, 1180
Endothelium-derived relaxing factor
nitric oxide, production by mesangial cells, glomerulus, 1435
renal response to nitric oxide synthesis inhibition, plasma renin activity, 1288
Endotoxemia, experimental, cytokine formation, rat glomeruli, 1783
Eosinophilia, cytokine responsiveness and, hemodialysis, 1244
Epidemiology, hypertension and development of complications, non-insulin dependent diabetes mellitus, Japan, S120

Epidermal growth factor
growth factor gene expression, murine polycystic kidney disease, 1378
rat 5/6 renal ablation model, 1113
Epinephrine, hormonal modulation of ionic permeability, human red blood cells, 1607
Epithelial cells
changes in, 1839
renal, pathogenesis of cysts, fluid secretion and cellular proliferation, 1843
tubular, transgenic cell expression of class II, initiation of immune renal injury, 1972
Epithelium, paretal, rat glomerular epithelial cells in culture, 1279
Erythrocytosis, posttransplant, 1653
Erythropoietin
hematocrit and blood pressure, normotensive and hyper-tensive rats, 182
- induced antinatriuresis, mediation by angiotensin II, perfused kidneys, 1583
platelet production in dialysis patients, 1672
subcutaneous, maintenance of hematocrit, chronic hemodialysis patients, 1717
therapy for anemia of end-stage renal disease, cost implications to Medicare, 1660
Ethics, death by withdrawal from dialysis, 1631
Ethnicity, increased lipoprotein(a) concentrations, chronic renal failure, 1156
Extracellular matrix
component messenger RNA expression, glomeruli, experimental focal glomerulosclerosis, 1387
interleukin-1-induced alterations, glomerular proteoglycans, autoradiography, 203
Fatty acids
omega-3, supplementation, primary nephrotic syndrome, 1321
palmitate transport, rat renal basolateral membrane vesicles, presence of albumin, 1920
Fetopothy, angiotensin-converting enzyme inhibitor, 1575
Fibrinolysis, glomerular, dysfunction, antilglomerular basement membrane antibody glomerulonephritis, 1753
Fibrosis, idiopathic retroperitoneal, 1748
Ficoll, determination of glomerular size-selectivity, 214
Fish oil, dietary, amelioration, ischemic acute renal failure, 1342
Fistula, arteriovenous, vascular access, concepts for the 1990s, 1
Flow cytometry, cytotoxic peripheral blood lymphocytes, acute renal graft rejection, 1220
Fluid
extracellular, acute insulin infusion and renal function, awake nondiabetic and diabetic rats, 1686
secretion and cellular proliferation, pathogenesis, renal epithelial cysts, 1843
Fluorescence imaging, angiotensin II-induced changes, smooth muscle calcium, rat renal arterioles, 1792
Foscamet, phosphate transport in brush border membranes, response to phosphotofatic acid, uremic rats, 1253
Fructose, feeding, glomerular structure, rats, 1330
Furo-2, angiotensin II-induced changes, smooth muscle calcium, rat renal arterioles, 1792
Gene
clusterin production, loss of renal function, obstructed rabbit kidney, 1163
cyclophillin-like, sodium excretion changes, nephrosis, 1710
determinants in human essential hypertension, S2 expression, regulation by tonicity, 121
growth factor, expression, murine polycystic kidney disease, 1378
heterogeneity and differences, glomerular hemodynamics, inbred colonies of Munich-Wistar rats, 66
mapping, experimental hypertension, 28
molecular approaches, development of nephropathy, insulin-dependent diabetes mellitus, 59
mutation, very early onset autosomal dominant polycystic kidney disease, characteristics, 1863
Genetics
predisposition to essential hypertension, recent-onset insulin-dependent diabetes, 534
screening, autosomal dominant polycystic kidney disease, 1442
Glomerular epithelial cells
cells in culture, characteristics of parietal epithelium, 1279
induction of cytoskeletal changes, vasoactive substances, 1134
production of endothelin-1, 1398
Glomerular filtration rate
acute insulin infusion and renal function, awake nondiabetic and diabetic rats, 1686
antihypertensive therapy, prevention of microalbuminuria progression to overt proteinuria, IDDM, 591
captopril-induced fall, cyclosporine-treated hypertensive patients, 1570
dietary protein and renal function, 1723
growth hormone and the kidney, 157
induction of renal arachidonate cytochrome P450 epoxygenase, uninephrectomy, counterregulation of hyperfiltration, 1496
modification of diet, baseline characteristics, renal disease, 1819
pathogenesis of glomerular injury, fawn-haired rat, 1775
serial, slope of, progression of diabetic glomerular disease, 1358
simultaneous measurements, radiotopic methods, patients without renal impairment, 108
Glomerulonephritis
antiglomerular basement membrane antibody, dysfunction, glomerular fibrinolysis, 1753
experimental crescentic, suppression by deoxyspergualin, 1765
kidney in sarcoidosis, 1555
Glomerulosclerosis
focal, extracellular matrix component mRNA expression, 1387
heterogeneous nature of renal lesions, type II diabetes, 1458
induction of renal arachidonate cytochrome P450 epoxygenase, uninephrectomy, counterregulation of hyperfiltration, 1496
large glomerular size, Pima Indians, 229
rat 5/6 renal ablation model, effect of epidermal growth factor, 1113
Glomerulus
albumin reflection coefficient measurement, 1260
angiotensin II receptor subtypes, 1643
cGMP accumulation in the kidney, effect of urodilatin, 1705
cytokine formation, experimental endotoxemia, rat, 1783
effects of blood pressure reduction, cyclosporine nephrotoxicity, rat, 1892
hemodynamics, genetic heterogeneity and differences, inbred colonies of Munich-Wistar rats, 66
injury, pathogenesis, fawn-haired rat, 1775
large size, Pima Indians, 229
mesangial cells and, production, endothelium-derived relaxing factor/nitric oxide, 1435
mesangium, species-specific properties, 1342
metalloproteinase activity, inverse correlation with injury, aging rat kidney, 1835
proteoglycan metabolism alterations, experimental non-insulin dependent diabetes mellitus, 1694
interleukin-1-induced alterations, autoradiography, 203
slope of serial glomerular filtration rate, progression, diabetic glomerular disease, 1358
structure of, effects of fructose feeding, rats, 1330
Glucocorticoids
induced changes, quantity and secretory capacity, individual rat somatotropes, 1428
thrombotic microangiopathy, 35
Glucose
acute insulin infusion and renal function, awake nondiabetic and diabetic rats, 1686
cellular lans, hypertension and insulin resistance, obesity and diabetes, 578
inhibition of phagocyte function, peritoneal dialysis fluid, 1508
transporters of the muscle, hyperglycemia effects, phlorizin, 1078
Glutamine, hepatic metabolism, ureagenesis, acid-base regulation, 1416
Glycoprotein, dimeric acidic: see Clusterin
Glycosaminoglycans, alterations in glomerular proteoglycan metabolism, experimental non-insulin dependent diabetes mellitus, 1694
G proteins, angiotensin II as a renal growth factor, 1531
Grantham, Jared J., Homer Smith Award, 1841, 1842
Growth factors
angiotensin II, kidney, 1531
gene expression, murine polycystic kidney disease, 1378
pathogenesis of renal epithelial cysts, fluid secretion, cellular proliferation, 1843
Growth hormone
gluocorticoid-induced changes, growth and secretory capacity, individual rat somatotropes, 1428
kidney and, 157
Hageman factor, bradykinin generation by dialysis membranes, role in anaphylactic reaction, 1563
H+·ATPase, absence of, cortical collecting tubules, Sjogren's syndrome and distal renal tubular acidosis, 264
Heart
complication, vascular access, concepts for the 1990s, 1 left ventricular mass and elevated blood pressure profile, autosomal dominant polycystic kidney disease, 1451
output, intradilatic food ingestion, hemodynamics and caffeine, 1813
Heat shock, how tonicity regulates gene expression, 121
Hematocrit
blood pressure and, effect of erythropoietin, normotensive and hypertensive rats, 182
maintenance of, subcutaneous erythropoietin, chronic hemodialysis patients, 1717
Hemodialysis
blood recirculation, intravenous catheters, 1978
calcium acetate as a phosphorus binder, 96
chronic, subcutaneous erythropoietin, maintenance of hematocrit, 1717
chronic in-center patients, knowledge, attitudes and behavior towards advance directives, 1405
compared to CAPD, patient survival, trends in 1980s, 1147
elevation of serum phosphate, parathyroid hormone levels, 1947
end-stage renal disease, variation in outcomes, 1738
eosinophilia and cytokine responsiveness, 1244
high-flux dialysis
  improvement, plasma lipoprotein profiles, 1409
  multivariate analysis, mortality and hospital admissions, 1227
normalization of uremic acidosis, high bicarbonate dialysate, 1804
predictors of mortality, 1613
renal bone disease, pediatric and young adult patients, 1938
vascular access, concepts for the 1990s, 1
Hemodynamics
  glomerular, genetic heterogeneity and differences, inbred colonies of Munich-Wistar rats, 66
  low protein intake and converting enzyme inhibition, additive antiproteinuric effect, 1307
  renal, predisposition to essential hypertension, insulin-dependent diabetic patients, 534
  renal functional reserve, healthy elderly subjects, 1374
Hemofiltration, continuous arteriovenous, total parenteral nutrition, protein catabolic rate, 1516
Hemolytic uremic syndrome, thrombotic microangiopathy, 35
Hemorrhage
  intracranial aneurysms, magnetic resonance angiography, 1874
  autosomal dominant polycystic kidney disease, 1874
  saccular intracranial aneurysms, autosomal dominant polycystic kidney disease, 88
Heparan sulfate
  alterations in glomerular proteoglycan metabolism, experimental non-insulin dependent diabetes mellitus, 1694
  extracellular matrix component mRNA expression, glomeruli, experimental focal glomerulosclerosis, 1387
Hepatocytes, glutamine metabolism and ureagenesis, acid-base regulation, 1416
HLA complex, frequency, racial variation, insulin-dependent diabetic nephropathy, 1467
Homer Smith Award, Jared J. Grantham, 1841, 1842
Hormones, modulation of ionic permeability, human red blood cells, 1607
Hyalinosis, heterogeneous nature of renal lesions, type II diabetes, 1458
Hydronephrosis, congenital, angiotensin or thromboxane receptor antagonism, rats, 1522
Hypercalcemia, kidney in sarcoidosis, 1555
Hypercholesterolemia
  Lovastatin treatment, renal transplant patients, cyclosporine, 1884
  severe, inhibition of cyclosporin A efficacy, children with nephrotic syndrome, 254
Hyperfiltration, dietary protein and renal function, 1723
Hyperglycemia, glucose transporters of the muscle, phlorizin, 1078
Hyperinsulinemia
  insulin resistance and insulinoma, normal blood pressure, S64
  obesity-associated hypertension, 1064
Hyperosmolality, acute and chronic renal failure, role of organic osmolytes, cerebral cell volume, 1913
Hyperparathyroidism, calcium acetate as a phosphorus binder, hemodialysis patients, 96
Hyperphosphatemia, elevation of serum phosphate, parathyroid hormone levels, hemodialysis, 1947
Hypertension
  abnormalities in Na+H+ antipporter activity, diabetic nephropathy, S50
  alterations in insulin receptor and substrate phosphorylation, hypertensive rats, S69
  antihypertensive therapy, experimental diabetes, S86
  associated diabetes mellitus, past and future, S1
  autosomal dominant polycystic kidney disease, 1442
  borderline hypertensive rats, effect of dietary potassium chloride, 188
  coronary artery disease and non-insulin dependent diabetes, cause and effect, S126
  persistent proteinuria, IDDM, S104
  cyclosporine-treated patients, captopril-induced fall, glomerular filtration rate, 1570
  development of complications, non-insulin dependent diabetes mellitus, Japan, S120
  diabetes and, molecular biology techniques, renin-angiotensin system, S18
  epidemial growth factor effect, rat 5/6 renal ablation model, 1113
  essential microalbuminuria and insulin resistance, NIDDM, S56
  predisposition to, development of diabetic nephropathy, 527
  predisposition to, recent-onset insulin-dependent diabetes, S34
  experimental, gene mapping, 28
  glomerular capillary, pathogenesis, glomerular injury in fawn-hooded rat, 1775
  human essential, identification, genetic determinants, S2
  insulin resistance and obesity and diabetes, cellular ions, S78
  roles of cell Ca2+, protein kinase C and Na+H+ antiport, 1049
  left ventricular mass, autosomal dominant polycystic kidney disease, children and young adults, 1451
  mild to moderate, pharmacologic therapy, generalization to diabetics, S135
  uninephrectomy, progression of renal failure, autosomal dominant polycystic kidney disease, 1119
  very early onset autosomal dominant polycystic kidney disease, characteristics, 1863
Hypertonicity, how tonicity regulates gene expression, 121
Hypertrophy
  angiotensin II as a renal growth factor, 1531
  induction of, no stimulation of Na+H+ exchange, renal cells, 1124
Hyponatremia, induction by vasopressin or desmopressin, 1600
Hypoosmolality, Induction of hyponatremia, vasopressin or desmopressin, 1600
Hypotension, dialysis-induced, hypertonic saline solutions, dextran, 1808
Hypoxia-reoxygenation injury, increased proximal tubular cell catalytic iron content, 116
ICAM-1, VCAM-1 and, kidney, 1201
Immune system, infectious morbidity, defects of phagocytic function, end-stage renal disease, 1541
Immunglobulin G, thrombotic microangiopathy, 35
Immunohistochemistry, suppression by deoxyspergualin, experimental crescentic glomerulonephritis, 1765
Immunosuppression, amelioration of renal allograft rejection, azaspirane SKF 105685, rats, 1680
Infant, congenital nephrotic syndrome, preemptive bilateral nephrectomy and dialysis, renal transplantation, 260
Infection
  complication, vascular access, concepts for the 1990s, 1
  morbidity and defects of phagocytic function, end-stage renal disease, 1541
Insolito, how tonicity regulates gene expression, 121
Insulin
  acute infusion, renal function, awake nondiabetic and diabetic rats, 1886
chronology of cellular events, derangements in pancreatic islet function, chronic renal failure, 1139

- dependent diabetes mellitus
  cost-effectiveness of screening and early treatment, nephropathy, S111
  molecular genetic approaches, development of nephropathy, S9
  persistent proteinuria, coronary artery disease and excess mortality, S104

- dependent diabetes of recent-onset, predisposition to essential hypertension, S34

hyperglycemia effects, glucose transporters of the muscle, phlorizin, 1078

resistance
  alterations in insulin receptor and substrate phosphorylation, hypertensive rats, S69
  close relationship to microalbuminuria, essential hypertension and NIDDM, S56
  hyperinsulinemia, obesity-associated hypertension, 1064
  hyperinsulinemia and insulinoma, normal blood pressure, S64
  hypertension/obesity/diabetes, cellular ions, S78
  resistance and hypertension, roles of cell Ca++ protein kinase C and Na+-H+ antiport, 1049

Insulins like growth factor-1, growth hormone and the kidney, 157

Insulinoma, hyperinsulinemia and insulin resistance, normal blood pressure, S64

Integrins, ICAM-1 and VCAM-1, kidney, 1201

Interleukin 1
  amelioration of renal allograft rejection, azaspirane SKF 105685, rats, 1680
  induced alterations, glomerular proteoglycans, autoradiography, 203

Interleukins, cytokine responsiveness, eosinophilia, hemodialysis, 1244

Interstitium, effects of blood pressure reduction, cyclosporine nephrotoxicity, rat, 1692

Intestine, P, transport adaptation, low phosphorus diet, uremic rats, 1930

Ions
  cellular, hypertension and insulin resistance, obesity and diabetes, S78
  permeability, hormonal modulation, human red blood cells, 1607
  lothalamate, lohexol and loxolate, induction of endothelin release, 58
  iron, catalytic, hypoxia-reoxygenation injury, proximal tubular cells, 116

Ischemia
  acute renal failure, amelioration, dietary fish oil administration, 1312
  complication, vascular access, concepts for the 1990s, 1 renal dysfunction, endothelin, modulating action of atrial natriuretic factor, 196

Japan, non-insulin dependent diabetes mellitus, hypertension and development of complications, S120

Ketoconazole, induction of renal arachidonate cytchrome P450 epoxygenase, uninephrectomy, counterregulation of hyperfiltration, 1496

Kidney, see also entries under Renal allograft rejection, amelioration, azaspirane SKF 105685, 1680
angiotensin II receptor subtypes, 1643

cGMP accumulation, effect of urocidin, 1705
disease, see Renal disease failure, see Renal failure function

acute insulin infusion, awake nondiabetic and diabetic rats, 1686
dietary protein, 1723

very early onset autosomal dominant polycystic kidney disease, characteristics, 1863

glomerular hemodynamics, genetic heterogeneity and differences, inbred colonies of Munich-Wistar rats, 66

growth factor, angiotensin II, 1531

injury
  interaction, complement and clusterin, 1172
  transgenic tubular cell expression, class II, 1972
  obstructed, clusterin production, loss of renal function, 1163
  P, transport adaptation, low phosphorus diet, uremic rats, 1930

rat 5/6 renal ablation model, 1113

remnant, oxygen consumption, hypermetabolism or hyperbole, 151

renal functional reserve, healthy elderly subjects, 1371

tissue concentration and urinary excretion pattern, sulfonfluorescein, rats, 1474

Lactic acidosis, chronic, AIDS and mitochondrial myopathy, 1212

Laminin, extracellular matrix component mRNA expression, glomeruli, experimental focal glomerulosclerosis, 1387

Lectin, binding of, detection of sialic acid, Limax flavus, 113

Leukocytes, suppression of experimental crescentic glomerulonephritis, deoxyspergualin, 1765

Leukotrienes, phospholipase A2 and signal transduction, 128

LFA-1, ICAM-1 and VCAM-1, kidney, 1201

Limax flavus, binding of a lectin, cultured cells, detection of sialic acid, 113

Lipids
  increased lipoprotein(a) concentrations, chronic renal failure, 1156
  omega-3 fatty acid supplementation, primary nephroptic syndrome, 1321

Lipoprotein, plasma profiles, improvement of, high-flux dialysis, 1409

Lipoprotein(a), increased concentrations, chronic renal failure, 1156

Lipoxygenases, phospholipase A2 and signal transduction, 128

Lisinopril, angiotensin-converting enzyme inhibitor fetoopathy, 1575

Listeria monocytogenes, unusual cases of peritonitis, continuous peritoneal dialysis, 1092

Lithium, red blood cell Na+/Li+ countertransport, sodium inactivation kinetics, diabetes, S41

Losartan, erythropoietin-induced antiangiogenesis, mediation by angiotensin II, perfused kidneys, 1583

Lovastatin, treatment of hypercholesterolemia, renal transplant patients, cyclosporine, 1884

Lymphocytes, cytotoxic peripheral blood, acute renal graft rejection, flow cytometry, 1220

Macraangiocapathy, hypertension and development of complications, non-insulin dependent diabetes mellitus, Japan, S120

Madin-Darby cells, characterization of cholinergic receptors, 170

Magnetic resonance angiography, intracranial aneurysms, autosomal dominant polycystic kidney disease, 1871

Major histocompatibility complex, class II, transgenic tubular cell expression, initiation of immune renal injury, 1972

Mayo, idiopathic retroperitoneal fibrosis, 1748

Medicare, cost implications, erythropoietin therapy, anemia of end-stage renal disease, 1660

γ-Melanocyte-stimulating hormone, peptides from N-terminal
University of Chicago, autosomal dominant polycystic kidney disease, 1442
University of Colorado, autosomal recessive polycystic kidney disease, variability of clinical presentation, 1558
University of Iowa, thrombotic microangiopathy, 35
University of Miami, secondary syphilis and the nephrotic syndrome, 1351
University of Michigan, unusual cases of peritonitis, continuous peritoneal dialysis, *Listeria monocytogenes*, 1092
Urea, recirculation, vascular access, concepts for the 1990s, 1
Ureagenesis, hepatic glutamine metabolism, acid-base regulation, 1416
Uremia
acidosis, normalization, hemodialysis patients, 1804
acute and chronic, role of organic osmolytes, cerebral cell volume, 1913
infectious morbidity, defects of phagocytic function, end-stage renal disease, 1541
phosphate transport in brush border membranes, response to phosphonoformic acid, rats, 1253
renal and intestinal P, transport adaptation, low phosphorus diet, rats, 1930
Urinary tract, obstruction, idiopathic retroperitoneal fibrosis, 1748
Urodilatin, cGMP accumulation in the kidney, 1705
Vascular disease, renal, death by withdrawal from dialysis, 1631
Vasoconstriction
angiotensin II-induced changes, smooth muscle calcium, rat renal arterioles, 1792
renal and systemic, endothelial albumin leakage, effect of cyclosporine, 51
Vasodilation, acetylcholine-induced, renal microvessels, cyclosporine-treated rats, 42
Vasopressin, desmopressin or, induction of hyponatremia, 1600
VCAM-1
expression in human renal allografts, 1180
ICAM-1 and, kidney, 1201
Vincristine, thrombotic microangiopathy, 35
Vitamin D₃, elevation of serum phosphate, parathyroid hormone levels, hemodialysis, 1947
Volume
cell, functional integrity, proximal tubule cells, 1900
-independent component, postdiuretic sodium retention, humans, 1878
Washington University, growth hormone and the kidney, 157
Water, balance and solute and cell cell volume, regulation of, central nervous system, 12
Yale University, posttransplant erythrocytosis, 1653
Xenotransplantation
natural immune barrier, 1189
renal transplantation, one size may not fit all, 162